Home > Drugs A – Z > Rifampin/Isoniazid (By mouth)
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Rifampin/Isoniazid (By mouth)

Treats tuberculosis (TB).

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Rifampin and isoniazid is a combination antibiotic and anti-infective medicine. This combination medication is used to treat tuberculosis (TB). It may be taken alone or with one or more other medicines for TB. To help clear up your tuberculosis (TB) infection completely, you must keep taking this medicine for the full time of treatment, even if you begin to feel better. This is very important. It… Read more
Brand names include
IsonaRif, Rifamate
Drug classes About this
Antitubercular Combination
Combinations including this drug

What works? Research summarized

Evidence reviews

Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis

The review aimed to determine the effectiveness and safety of daily short-course therapy with rifampin plus isoniazid compared with standard isoniazid therapy for latent tuberculosis infection. The authors concluded that the two approaches were similar in terms of efficacy, side-effects and death. Overall, this was a well-conducted review, and the authors' conclusion is likely to be reliable.

4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity

The authors concluded that four months of rifampin was superior to nine months of isoniazid in the treatment of latent tuberculosis infection in terms of safety and compliance, but further research is needed into tuberculosis reactivation. Given the limited evidence base and potential for bias in the review, the authors? conclusions regarding safety and compliance should be interpreted with caution.

Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis

This well-conducted review compared the efficacy and safety of rifampicin plus pyrazinamide (RZ) with isoniazid for the treatment of latent tuberculosis infection in HIV-positive and HIV-negative individuals. The authors concluded that both regimens were effective and that mortality was equivalent. However, in HIV-negative patients, RZ groups experienced more adverse events. This conclusion should be treated with caution.

See all (12)

PubMed Health Blog...

read all...